Cologuard screens for colorectal cancer and precancerous growths by looking for three categories of biomarkers in a stool sample: traces of blood (hemoglobin), abnormal DNA methylation patterns on two specific genes, and mutations in a cancer-associated gene called KRAS. These markers, taken individually, each capture a different biological signal that tumors and precancerous polyps give off. But Cologuard does not rely on any single marker in isolation. Instead, it feeds all the results into an algorithm that produces a single positive or negative score, which is what makes it a “multitarget” stool DNA test rather than a simple blood-in-stool check.
Hemoglobin in Stool
The most intuitive of the three biomarkers is hemoglobin, the oxygen-carrying protein in red blood cells. Colorectal tumors and large polyps tend to bleed, often in tiny amounts you would never notice by looking. When hemoglobin from that bleeding makes its way into stool, an immunoassay can detect it. This is the same principle behind the standalone fecal immunochemical test (FIT), which has been the backbone of large-scale colorectal cancer screening programs worldwide.1PubMed Central. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase Cologuard essentially incorporates a FIT-style hemoglobin immunoassay as one component of its broader panel.
Hemoglobin detection is good at catching tumors that are actively bleeding, but it has blind spots. Not every cancer bleeds consistently, and some precancerous polyps barely bleed at all. Bleeding can also be intermittent, so the timing of your sample matters. That inconsistency is a key reason Cologuard layers DNA markers on top of the hemoglobin test: the DNA signals do not depend on whether a growth happened to bleed on the day you collected your sample.
DNA Methylation Markers
The second biomarker category involves changes to the way two genes, BMP3 and NDRG4, are chemically modified. In healthy cells, these genes function normally. But in many colorectal cancers and advanced precancerous lesions, the promoter regions of BMP3 and NDRG4 pick up extra methyl groups, a process called aberrant methylation. This essentially silences the genes, and silencing tumor-suppressing genes is one of the early steps in how normal colon cells go rogue.2PubMed Central. Stool DNA methylation assays in colorectal cancer screening
What makes methylation markers especially useful for screening is that they show up early in the process of a cell becoming cancerous. A polyp does not need to be large or bleeding for its cells to shed DNA carrying these methylation signatures into the stool. That gives Cologuard a way to flag growths that a hemoglobin-only test might miss. The assay measures the degree of methylation quantitatively rather than just checking whether it exists, which helps separate meaningful signals from background noise.
BMP3 and NDRG4 were not chosen at random. Researchers evaluated many candidate methylation targets and found these two had the best combination of sensitivity for colorectal neoplasia and specificity, meaning they reliably light up in cancer or precancer without triggering too many false alarms from normal tissue. Their inclusion alongside the hemoglobin assay is what pushed the original Cologuard test to outperform standalone FIT in sensitivity.3PubMed. Multitarget Stool DNA Testing for Colorectal-Cancer Screening
KRAS Gene Mutations
The third biomarker is mutations in the KRAS gene. KRAS is a well-known oncogene, meaning that when it picks up certain point mutations, it can push cells toward uncontrolled growth. KRAS mutations are found in a significant share of colorectal cancers and appear early enough in the cancer development process to be useful as a screening signal. Cologuard’s assay targets specific KRAS mutations and looks for them in DNA that tumor or polyp cells have shed into the stool.
Research using highly sensitive detection methods has shown that KRAS mutations can be picked up from stool samples in a large majority of patients whose tumors carry the mutation, including patients with early-stage disease. In one study using droplet digital PCR, stool-based detection caught the KRAS G12D mutation in eight out of ten patients whose tumors harbored it, and six of those eight were early-stage cancers.4PubMed Central. Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR That early-stage detectability is exactly what you want in a screening biomarker.
Not all colorectal cancers carry KRAS mutations, which is why this marker works as part of a panel rather than standing alone. A tumor might have KRAS mutations but minimal methylation changes, or vice versa. Another might bleed enough for the hemoglobin assay to catch it while producing weaker DNA signals. By testing for all three, the test casts a wider net than any single biomarker could.
The Reference Marker and the Algorithm
You may come across a fourth name in the technical details: β-actin (beta-actin). This is not a cancer biomarker per se. β-actin is a gene expressed in virtually all human cells, so its DNA shows up in any stool sample containing human cells. Cologuard measures it as a reference marker to confirm that the sample contains enough human DNA for the other assays to work reliably. Think of it as a quality-control check rather than a disease signal.3PubMed. Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Once all assays have run, Cologuard feeds the results into a logistic-regression algorithm. The algorithm weighs the hemoglobin level, the degree of BMP3 and NDRG4 methylation, and the KRAS mutation findings, then produces a single numerical score. In the original version, a score of 183 or above was classified as positive. You never see the individual biomarker results on your report; you get a positive or negative result that reflects the combined picture.
How Sensitive and Specific Is the Combined Test
Sensitivity measures how well a test catches actual cancers. Specificity measures how well it avoids flagging people who do not have cancer or advanced precancerous lesions. These two are in constant tension: dial up sensitivity and you tend to get more false positives; tighten specificity and you risk missing some real cancers.
The original Cologuard (approved in 2014) was evaluated in a large prospective study comparing it head-to-head with FIT in average-risk adults. The multitarget stool DNA test showed higher sensitivity for colorectal cancer than FIT, but at the cost of lower specificity.3PubMed. Multitarget Stool DNA Testing for Colorectal-Cancer Screening In plain terms, Cologuard caught more cancers than a blood-in-stool test alone, but it also produced more false alarms.
A next-generation version of the test was subsequently developed to address that specificity gap. In a prospective study of asymptomatic adults 40 and older, the updated test maintained higher sensitivity for both colorectal cancer and advanced precancerous lesions compared to FIT, though specificity was still lower than FIT’s.5PubMed. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening The trade-off has improved but has not disappeared entirely.
What a Positive Result Actually Means
A positive Cologuard result does not mean you have colorectal cancer. It means the algorithm detected enough combined signal from the biomarkers to warrant a follow-up colonoscopy. Real-world data paint a sobering picture of what happens after a positive result: in one study examining follow-up colonoscopies after positive Cologuard results, only about 6% of patients were diagnosed with colorectal cancer, roughly a third had benign polyps, and about 62% had no significant findings at all.6PubMed Central. From Detection to Delay: Real-World Gaps in Post-Cologuard Colonoscopy Adherence
Those numbers reflect the inherent challenge of screening asymptomatic people. Most people being screened do not have cancer, so even a reasonably specific test will flag some healthy people. The roughly one-third who had benign polyps represent a genuine benefit of screening, since some of those polyps could have eventually become cancerous. But the majority with no findings had what amounted to a false alarm.
False positives carry real consequences beyond the inconvenience of a colonoscopy. Qualitative research has found that people who receive false-positive results from colorectal cancer screening can experience lasting worry, changes in how they think about their health, and in some cases reduced willingness to participate in future screening.7PubMed Central. Psychosocial consequences of receiving false-positive colorectal cancer screening results: a qualitative study The anxiety does not always resolve quickly after a clean colonoscopy. That psychological toll is one reason researchers keep working to improve specificity.
How Cologuard Fits Among Other Screening Options
Cologuard is not the only way to screen for colorectal cancer, and understanding where it sits among alternatives helps you make sense of what it offers. Most screening guidelines for average-risk adults recommend either colonoscopy on a longer interval or a stool-based test on a shorter one.8PubMed. Colorectal cancer screening guidelines for average-risk and high-risk individuals: A systematic review A typical colonoscopy interval is every ten years, while annual FIT is the other mainstay. Cologuard falls somewhere in between: it is recommended every three years.
The stool DNA test’s advantage over FIT alone is sensitivity. It catches a higher proportion of cancers and advanced precancerous lesions because the DNA markers detect biological changes that blood-based hemoglobin detection misses.9PubMed Central. Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests The trade-off is cost. Cologuard is substantially more expensive than FIT, which matters both to individuals and to health systems thinking about population-level screening. Cost-effectiveness modeling has found that while Cologuard is effective, strategies like colonoscopy every ten years and annual FIT tend to deliver similar or better outcomes at lower cost per quality-adjusted life-year gained.10PubMed Central. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
Newer blood-based screening tests (sometimes called liquid biopsies) have also entered the conversation. Modeling studies comparing these blood tests with stool-based methods and colonoscopy have generally found that FIT, colonoscopy, and multitarget stool DNA remain less costly and more effective than the current generation of blood-based biomarker tests.11PubMed Central. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy Blood-based tests may eventually improve enough to compete, but for now, stool tests and colonoscopy remain the workhorses.
Why Sample Handling Matters
Because Cologuard depends on detecting trace amounts of DNA in stool, the integrity of that DNA during collection and shipping is critical. DNA degrades quickly in an unprotected stool sample. Research on stool DNA stability has shown that without a preservative buffer, stool DNA can break down drastically within just two hours at body temperature, to the point where no amplification signal can be detected. With a preservative buffer, DNA remains stable for at least a week even at elevated temperatures.12BioMed Central. A simplified multiplex methylated DNA testing for early detection of colorectal cancer in stool DNA
This is why the Cologuard kit includes a collection container with built-in preservative solution. You are not simply mailing a raw stool sample. The preservative stabilizes both the DNA and the hemoglobin so that the biomarkers remain detectable during shipping. If you leave the sample sitting for days before adding it to the preservative container, or if the kit is damaged and the preservative leaks, you risk an unusable sample. Following the collection instructions closely is not just a formality; it directly affects whether the test can do its job.
Completing the Test and Follow-Through
One of Cologuard’s selling points is convenience: you collect a sample at home and ship it to a lab, avoiding the prep and sedation of a colonoscopy. But convenience only helps if people actually complete the process. Real-world adherence data show that about 70% of people who are shipped a kit return a valid sample, with the average turnaround from kit shipment to receipt of a usable test being roughly 26 days.13Journal of Health Economics and Outcomes Research. Impact of Digital Navigation on Screening Adherence With the Multi-Target Stool DNA Test That means roughly three in ten people who receive a kit never complete it. Digital reminders via text and email have been shown to meaningfully improve completion rates and shorten return times.
An arguably bigger adherence gap occurs after a positive result. The entire point of Cologuard is to identify people who need a diagnostic colonoscopy. But research has documented significant delays and outright failure to follow through on that colonoscopy. If you receive a positive Cologuard result and do not get a colonoscopy, the screening has not accomplished anything. The test identified a signal; ignoring the signal does not make it go away.6PubMed Central. From Detection to Delay: Real-World Gaps in Post-Cologuard Colonoscopy Adherence
Who Cologuard Is and Is Not Designed For
Cologuard was developed and validated for asymptomatic adults at average risk for colorectal cancer. Most guidelines now recommend starting screening at age 45 for average-risk individuals, a shift from the previous threshold of 50, and continuing through at least age 75.8PubMed. Colorectal cancer screening guidelines for average-risk and high-risk individuals: A systematic review If you have symptoms like unexplained rectal bleeding, persistent changes in bowel habits, or unexplained weight loss, Cologuard is not the right test. Those symptoms call for diagnostic evaluation, typically a colonoscopy, not a screening test designed for people who feel fine.
People with a personal history of colorectal cancer, inflammatory bowel disease, or certain hereditary cancer syndromes are also generally not candidates for Cologuard. These conditions change the baseline risk profile enough that a stool-based screening test calibrated for average-risk populations may not perform as expected. High-risk individuals typically need colonoscopy on a more frequent schedule, sometimes every one to five years depending on their specific situation.
It is also worth knowing that a negative Cologuard result does not guarantee you are cancer-free. No screening test catches every case. Some cancers and precancerous lesions will not shed enough DNA or bleed enough to trigger the algorithm. The recommended three-year screening interval is designed to catch growths that may have been too small or biologically quiet during the previous test. Skipping your next screening because the last one was negative defeats the purpose of interval-based testing.
Emerging Stool-Based Approaches
The multitarget stool DNA approach is not standing still. Beyond the next-generation version of Cologuard already studied, researchers are exploring stool RNA tests as a potential complement or alternative. A multitarget stool RNA test evaluated in adults 45 and older showed roughly 94% sensitivity for colorectal cancer and 46% sensitivity for advanced adenomas.14PubMed. Multitarget stool RNA test for colorectal cancer screening RNA-based markers reflect active gene expression rather than static DNA changes, which could provide a complementary biological window into what is happening in the colon.
The broader direction of the field is toward panels that combine multiple types of molecular signals, whether DNA, RNA, protein, or even microbial signatures, to push both sensitivity and specificity higher simultaneously. Each generation of these tests adds or refines markers based on what the previous generation missed or falsely flagged. For now, Cologuard’s three-biomarker panel of hemoglobin, methylation markers, and KRAS mutations represents the most widely used multitarget stool test in clinical practice, but the landscape is evolving rapidly enough that the version available five years from now may look quite different from today’s.